Insulin X10 revisited: A super-mitogenic insulin analogue

Diabetologia

Volumn 54, Issue 9, 2011, Pages 2226-2231

  Hansen, B F ^a   Kurtzhals, P ^a   Jensen, A B ^b   Dejgaard, A ^a   Russell Jones, D ^c  

^a NOVO NORDISK A S   (Denmark)

^b Bryggen Medical Center   (Norway)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Dissociation rate; IGF 1 receptor; Insulin analogue; Insulin receptor; Insulin X10; Mitogenicity; Receptor affinity; Review

Indexed keywords

FOCAL ADHESION KINASE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN[A8 HISTIDINE B4 HISTIDINE B10 GLUTAMATE B27 HISTIDINE]; INSULIN[A8 HISTIDINE]; INSULIN[B10 ASPARTIC ACID]; INSULIN[B10 GLUTAMATE B30 DETHREONINE]; INSULIN[B9 ASPARTIC ACID B27 GLUTAMATE]; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SHC; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST TUMOR; DOSE RESPONSE; DRUG ABSORPTION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INSULIN; INSULIN, SHORT-ACTING; MAMMARY NEOPLASMS, EXPERIMENTAL; MITOGENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 80054685557     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2203-8     Document Type: Article

References (38)

1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167 (Pubitemid 38747263)
2. Ogunleye AA, Ogston SA, Morris AD, Evans JM (2009) A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 101:1199-1201
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578 (Pubitemid 351232031)
4. Tran TT, Medline A, Bruce WR (1996) Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomark Prev 5:1013-1015 (Pubitemid 26415875)
5. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1038
6. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
7. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765, erratum 52:2469
8. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
9. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
10. Brange J, Ribel U, Hansen JF et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682
11. Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci USA 84:6408-6411 (Pubitemid 18002808)
12. Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diab Metab Rev 8:259-285
13. Blundell T, Dodson G, Hodgkin D, Mercola D (1972) Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279-402
14. Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:942-948
15. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR (1991) Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on mealrelated plasma glucose excursions in type I diabetic subjects. Diabetes Care 14:571-577
16. Nielsen FS, Jørgensen LN, Ipsen M, Voldsgaard AI, Parving HH (1995) Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592-598
17. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjørn S, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495
18. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307-313
19. Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005 (Pubitemid 30349423)
20. Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40(Suppl 2):S54-S61 (Pubitemid 27306923)
21. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19-25 (Pubitemid 27107371)
22. Sommerfeld MR, Müller G, Tschank G et al (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5:e9540
23. Kohn WD, Micanovic R, Myers SL et al (2007) pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 28:935-948 (Pubitemid 46349342)
24. Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-279 (Pubitemid 26113562)
25. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534-2543 (Pubitemid 350060636)
26. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441
27. Berti L, Kellerer M, Capp E, Häring HU (1997) Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia 40:606-609 (Pubitemid 27186799)
28. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48:611-617 (Pubitemid 29230522)
29. Oleksiewicz MB, Bonnesen C, Hegelund AC et al. (2010) Comparison of intracellular signalling by insulin and the hyper-mitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J Appl Toxicol. doi:10.1002/jat.1590
30. Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753
31. Pollak M, Russell-Jones D (2010) Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 64:628-636
32. Hansen BF, Pia J (2010) Detailed analysis of insulin receptor phosphorylation after stimulation with insulin X10. Ir10: XIth International Symposium on Insulin receptors and Insulin Action (Abstract no. P09.95). http://www.irm10.com/Final-Abstract-Book.pdf. Accessed 16 March 2011
33. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
34. Glendorf T, Knudsen L, Stidsen CE et al. (2010) Evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogs. Ir10: XI International Symposium on Insulin Receptors and Insulin Action. Naples, Italy, 2010. Poster P09.94. www.irm10.com/Final-Abstract-Book.pdf. Accessed 16 May 2011
35. Hansen BF, Stidsen CE, Glendorf T, Lundby A, Hegelund AC, Bonnesen C (2010) Safety analysis of basal insulins: mitogenic potency and receptor binding. Diabetologia 53(suppl 1):S22
36. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695 (Pubitemid 35190951)
37. Slaaby R, Schäffer L, Lautrup-Larsen I et al (2006) Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem 281:25869-25874 (Pubitemid 44401792)
38. Bonnesen C, Nelander GM, Hansen BF et al (2010) Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin. Cell Biol Toxicol 26:293-307